文献速递疼痛医学

鞘内药物输注系统在慢性疼痛少见适应症中的叙述性综述

Uncommon indications in chronic pain for intrathecal drug delivery systems: a narrative review of the literature.
PubMed 文献 · Reg Anesth Pain Med · 2026-09-08

本文为叙述性综述,检索PubMed、Embase、Web of Science、CINAHL和Cochrane数据库,评估鞘内药物输注系统(IDDS)用于脊髓损伤相关疼痛、横贯性脊髓炎、糖尿病痛性神经病变、带状疱疹后神经痛和颅面部疼痛等少见难治性疼痛适应症的有效性与临床实用性。现有证据主要来自观察性研究和小型临床试验,提示IDDS可能在精心选择的患者中提供有意义的镇痛,但镇痛幅度和反应持久性可变。

要点

  • IDDS常用于癌痛和椎板切除术后综合征,少见适应症证据有限。
  • IDDS可能对中枢性、周围性和面部神经病理性疼痛提供有意义的镇痛。
  • 镇痛幅度和反应持久性可变,需个体化选择患者。

核心结论

  • 基于有限证据,IDDS可能为难治性少见疼痛综合征患者提供有意义的临床获益。

研究设计与样本

  • 叙述性综述,检索PubMed、Embase、Web of Science、CINAHL和Cochrane数据库,并手工筛查参考文献列表。
  • 由三名评审员使用Covidence筛选文献,纳入IDDS用于难治性少见疼痛适应症的研究。
  • 排除非英语研究、动物研究、关注非疼痛适应症的研究以及无全文的摘要。
  • 因异质性和以描述性数据为主,采用描述性分类进行叙述性分析。

主要发现

  • IDDS用于特定疼痛适应症难治性疼痛的证据主要来自观察性研究和小型临床试验。
  • 当前证据提示IDDS可能在精心选择的中枢性、周围性和面部神经病理性疼痛患者中提供有意义的镇痛。
  • 镇痛幅度和反应持久性可变。
  • 这些发现可能反映因临床实践中选择性使用该疗法而导致的有限证据。

临床怎么用

  • 在精心选择的难治性少见疼痛综合征患者中,可考虑IDDS以提供有意义的临床获益。
  • 需认识到现有证据有限,镇痛效果和持久性存在个体差异。

局限性

  • 证据主要来自观察性研究和小型临床试验,异质性大且以描述性数据为主。
  • 临床实践中选择性使用该疗法可能导致证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intrathecal drug delivery systems (IDDS) have been used successfully for a number of refractory chronic pain conditions. The most common pain indications for the use of IDDS include cancer-related pain and postlaminectomy syndrome. IDDS can also be used to treat a variety of other less common refractory pain conditions, including central neuropathic pain, peripheral neuropathic pain and craniofacial pain. The aim of this article was to review the existing literature on the efficacy and clinical utility of IDDS for the management of uncommon pain indications, including spinal cord injury-related pain, transverse myelitis, diabetic painful neuropathy, postherpetic neuralgia and craniofacial pain to inform clinicians on the state of the current evidence of IDDS use in these challenging pain conditions. PubMed, Embase, Web of Science, CINAHL and Cochrane databases were searched with keywords. Additionally, reference lists of retrieved articles and relevant reviews were manually screened to identify additional publications. Articles were screened for relevance using Covidence by three reviewers. Eligible studies included the use of IDDS for refractory uncommon pain conditions. Exclusion criteria included non-English studies, animal studies, studies that focused on non-pain indications and abstracts without accompanied full text. Given heterogeneity and largely descriptive data, findings were analyzed narratively by descriptive categories.The use of IDDS for refractory pain in patients with select pain conditions is supported primarily by observational studies and small clinical trials. Current evidence suggests that the IDDS may provide meaningful analgesia in carefully selected patients with central and peripheral pain, and facial neuropathic pain; however, the magnitude of pain relief and durability of response is variable. These findings are likely reflective of the limited evidence as a result of selective utilization of this therapy in clinical practice. Based on limited evidence, IDDS may provide meaningful clinical benefit in patients with refractory uncommon pain syndromes. Future research can help to define the use of IDDS in this challenging patient population.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Singla P, Li G, Kohan L, et al. Uncommon indications in chronic pain for intrathecal drug delivery systems: a narrative review of the literature. Reg Anesth Pain Med. 2026. PMID: 42710942. doi:10.1136/rapm-2025-107220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。